# Trial to Assess the Safety and Effects of Vorapaxar in Japanese Subjects With Acute Coronary Syndrome (P04772; MK-5348-016)

> **NCT00684203** · PHASE2 · COMPLETED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 120 (actual)

## Conditions studied

- Atherosclerosis
- Myocardial Ischemia
- Myocardial Infarction

## Interventions

- **DRUG:** Vorapaxar
- **DRUG:** Placebo
- **DRUG:** Aspirin
- **DRUG:** Clopidogrel

## Key facts

- **NCT ID:** NCT00684203
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-12-01
- **Primary completion:** 2007-10-01
- **Final completion:** 2007-10-01
- **Target enrollment:** 120 (ACTUAL)
- **Last updated:** 2017-05-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00684203

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00684203, "Trial to Assess the Safety and Effects of Vorapaxar in Japanese Subjects With Acute Coronary Syndrome (P04772; MK-5348-016)". Retrieved via AI Analytics 2026-07-13 from https://api.ai-analytics.org/clinical/NCT00684203. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*